Company: Ironwood Pharmaceuticals, Inc.
Headquarters: Boston, Massachusetts, USA
Founded: 1998 (as Microbia, renamed 2008)
Ticker: IRWD (NASDAQ)
Employees: ~350
Market Cap: ~$1.5B (2024)
Ironwood Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal (GI) disorders. The company is best known for Linzess (linaclotide) for irritable bowel syndrome with constipation and chronic idiopathic constipation, a guanylate cyclase-C (GC-C) agonist that has become a leading prescription therapy[1].
Ironwood's GI focus has significant relevance for Parkinson's disease patients, who experience among the highest rates of constipation of any patient population. The company's research into GC-C biology and GI motility mechanisms positions it to address autonomic-related GI dysfunction that affects 60-80% of PD patients[2].
Ironwood's core technology revolves around GC-C receptor agonism:
Mechanism of Action:
Pharmacological Benefits:
Patients with Parkinson's disease suffer from constipation through multiple mechanisms:
Linaclotide addresses the transit and secretion components, making it a targeted therapy for PD-associated slow-transit constipation. Unlike stimulant laxatives, linaclotide does not cause colonic inflammation and can be used chronically without the risk of laxative-induced colonic damage.
| Attribute | Details |
|---|---|
| Brand Name | Linzess |
| Generic Name | Linaclotide |
| Formulation | Oral capsules (72 mcg, 145 mcg) |
| Indication | IBS-C, Chronic Idiopathic Constipation |
| Dosing | Once daily on empty stomach, 30 min before first meal |
| FDA Approval | August 2012 (IBS-C), September 2012 (CIC) |
| Partner | AbbVie (formerly Forest Laboratories) for US commercialization |
| Revenue | >$1B annually (combined with Constella outside US) |
Efficacy:
Safety Profile:
marketed as Constella outside the United States through AbbVie/partners, covering EU, Canada, and other markets.
While not specifically developed for PD, linaclotide has been evaluated in context of PD-associated constipation:
| Program | Indication | Mechanism | Status |
|---|---|---|---|
| IW-3300 | Functional GI disorders | GC-C agonist (novel formulation) | Preclinical |
| CNP analogs | Various GI targets | Guanylate cyclase modulation | Discovery |
Ironwood partnered with AbbVie (formerly Forest Laboratories) for US commercialization of linaclotide:
Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2023. ↩︎
Fasano A, et al. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2015. ↩︎